Price
750
-0.39%52W Range
Market Cap
₹11,804.55 Cr
Traded: ₹19.24 Cr (0.16%) 0.0x
Free Float: ₹787.36 Cr (2.44% of FF traded)
Volume · 60D trend
2.56 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | +16.0% | +16.0% | +29.0% | -- | -7.0% | Stable |
| Return | -- | -- | -- | +45.0% | -- | -- |
| Sales | +10.0% | +10.0% | +6.0% | -- | +9.0% | Stable |
| ROE | -- | +6.0% | +10.0% | -- | -- | Accelerating |
Quarterly Results
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,167 | 1,158 | 1,160 | 1,018 | 1,024 | 1,056 | 1,010 | 1,033 | 1,019 | 944 | 1,083 | 1,181 | 970 |
| Expenses | 992 | 1,006 | 1,013 | 923 | 895 | 962 | 889 | 912 | 891 | 941 | 989 | 1,029 | 1,095 |
| Operating Profit | 175 | 152 | 147 | 94 | 129 | 94 | 121 | 121 | 128 | 3 | 93 | 152 | -125 |
| OPM % | 15.0% | 13.0% | 13.0% | 9.0% | 13.0% | 9.0% | 12.0% | 12.0% | 13.0% | 0.3% | 9.0% | 13.0% | -13.0% |
| Other Income | 30 | 34 | 16 | 32 | 27 | 26 | 19 | 17 | 7 | 10 | 10 | -21 | 8 |
| Interest | 25 | 24 | 24 | 23 | 23 | 5 | 5 | 12 | 13 | 12 | 12 | 14 | 12 |
| Depreciation | 41 | 40 | 40 | 38 | 37 | 40 | 45 | 35 | 34 | 34 | 32 | 30 | 30 |
| Profit Before Tax | 139 | 121 | 100 | 66 | 96 | 75 | 91 | 92 | 87 | -33 | 59 | 87 | -159 |
| Tax % | 27.0% | 33.0% | 32.0% | 35.0% | 32.0% | -99.0% | 27.0% | 27.0% | 30.0% | 20.0% | -229.0% | 62.0% | 18.0% |
| Net Profit | 101 | 81 | 68 | 43 | 65 | 150 | 66 | 67 | 61 | -39 | 195 | 33 | -187 |
| Exceptional Items | -- | -2 | -18 | 0 | 0 | 8 | 5 | 4 | 0 | 0 | 1 | -27 | 0 |
| EPS (Rs) | 6.3 | 5.4 | 4.2 | 2.6 | 4.0 | 9.4 | 4.1 | 4.1 | 4.1 | -2.9 | 13.5 | 2.2 | -13.2 |
| Sales Growth (YoY) | 14.0% | 9.7% | 14.8% | -1.4% | 0.5% | 11.9% | -6.7% | -12.5% | 5.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 0.8% | -0.2% | 13.9% | -0.6% | -3.0% | 4.5% | -2.2% | 1.4% | 7.9% | -12.8% | -8.3% | 21.8% | -- |
| OP Growth (YoY) | 35.7% | 61.7% | 21.5% | -22.3% | 0.8% | 3033.3% | 30.1% | -20.4% | 202.4% | -- | -- | -- | -- |
| OP Growth (QoQ) | 15.1% | 3.4% | 56.4% | -27.1% | 37.2% | -22.3% | 0.0% | -5.5% | 4166.7% | -96.8% | -38.8% | 221.6% | -- |
| Profit Growth (YoY) | -- | -39.0% | 27.0% | -35.0% | 6.0% | 442.0% | -68.0% | 50.0% | 132.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | 57.6% | -42.6% | 1.7% | -37.4% | -1.2% | 424.6% | -69.4% | 86.5% | 131.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 18.0% | 27.8% | 62.5% | -35.7% | -57.0% | 126.6% | 0.0% | 1.5% | 241.2% | -121.3% | 509.9% | 116.9% | -- |
| OP Margin | 15.0% | 13.1% | 12.7% | 9.2% | 12.6% | 8.9% | 12.0% | 11.7% | 12.6% | 0.3% | 8.6% | 12.9% | -12.9% |
| Net Margin | 8.7% | 7.0% | 5.9% | 4.2% | 6.3% | 14.2% | 6.5% | 6.5% | 6.0% | -4.1% | 18.0% | 2.8% | -19.3% |
| Material Cost % | -- | 57.0% | 59.0% | 58.0% | 57.0% | 61.0% | 60.0% | 58.0% | 58.0% | 60.0% | 63.0% | 59.0% | 61.0% |
| Employee Cost % | -- | 17.0% | 16.0% | 19.0% | 17.0% | 17.0% | 17.0% | 17.0% | 17.0% | 17.0% | 15.0% | 14.0% | 16.0% |
| P/S | 2.62 | 2.52 | 2.00 | 1.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 40.47 | 43.03 | 26.74 | 24.24 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.56 | 3.31 | 2.70 | 2.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation of Schedule of the Investors/Analysts Meet
Transcript of Investors/Analysts conference call for the unaudited financial results of Q1 FY 27
Intimation of Schedule of the Investors/Analysts Meet to be held on August 14, 2026
Link of audio recording of Investors/Analysts Conference Call
Newspaper Publication
Monitoring Agency Report for the quarter ended June 30, 2026
Un-audited Financial Results for the Quarter ended 30th June, 2026
Press Release
Investor Presentation
Un-audited Financial Results for the Quarter ended 30th June, 2026
Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia, to consider and approve the un-audited ....
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of Oriflame India''s Manufacturing Business
Voting Results and Scrutinizer''s Report of the 22nd Annual General Meeting
Proceedings of the 22nd Annual General Meeting of the Company
Certificate pursuant to Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018
Update on penalty imposed by the Deputy Commissioner of State Tax, Gujarat, on Maxcure Nutravedics Limited, wholly owned subsidiary of the Company
Closure of Trading Window
Newspaper Advertisements of the 22nd Annual General Meeting of the Company
Notice and Integrated Annual Report for the Financial Year 2025-26 to those members who have not registered their e-mail ID''s
Business Responsibility and Sustainability Reporting for the FY 2025-26
Integrated Annual Report for the FY 2025-26
Notice of the 22nd Annual General Meeting
Newspaper Advertisement- Information regarding 22nd AGM and Final & Special Dividend
Intimation of Schedule of the investor/analysts meets
Intimation of Schedule of the Investor/Analyst Meet
Intimation of Schedule of the Investor/Analysts Conference Call (group meet)
Receipt of Assessment Order(s) by certain subsidiaries from Income Tax Department
Transcript on investors/analysts conference call held for un-audited financial results of Q4 FY 2025-26 and audited financial results for FY 2025-26
Receipt of Assessment Order(s) from Income Tax Department
Link of Audio Recording of Investor/Analyst Conference Call
Update on Disruption in Operations at come of the Manufacturing Sites at Haridwar
Annual Secretarial Compliance Report for the FY 2025-26
Update on Disruption in Operations at some of the manufacturing sites at Haridwar
Intimation regarding Newspaper Publication
Investor Presentation
Monitoring Agency Report for the quarter ended on 31st March, 2026
Press Release
Intimation of Disruption in Operations at some of the manufacturing sites at Haridwar
The Board has fixed Friday, July 03, 2026, as the "Record Date" to ascertain the eligibility of the shareholders for the payment of final cum special dividend.
Changes in Senior Management Personnel
Re-appointment of Cost Auditors for the FY 2026-27
Appointment of Internal Auditors for the FY 2026-27
Financial Results for the quarter and year ended 31st March, 2026
Outcome of Board meeting for Financial Results
Recommendation of Final cum Special Dividend
Intimation of Schedule of the Analysts Conference Call for Q4 results and audited financials for FY2026
Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Board Meeting ....
Intimation of ESG Rating
Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of the Company has executed a lease deed to purchase an Industrial plot.
Intimation of reaffirmed/ new credit rating under Reg 30 of SEBI (LODR) Regulations, 2015
Credit Ratings
6Concalls
9Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Sep 2024
30 Sept 2024Nov 2023
30 Nov 2023Held by ETFs
2 ETFs hold akums · sorted by weight
Held by Mutual Funds
17 schemes hold akums · sorted by weight